N-{[1-phenyl-4-(3-methoxyphenyl)piperidin-4-yl]methyl}-N'-(4-tert-butoxycarbonylamino-2,6-diisopropylphenyl)urea | 620593-39-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-{[1-phenyl-4-(3-methoxyphenyl)piperidin-4-yl]methyl}-N'-(4-tert-butoxycarbonylamino-2,6-diisopropylphenyl)urea
• 英文别名: tert-butyl N-[4-[[4-(3-methoxyphenyl)-1-phenylpiperidin-4-yl]methylcarbamoylamino]-3,5-di(propan-2-yl)phenyl]carbamate
• CAS: 620593-39-7
• 化学式: C₃₇H₅₀N₄O₄
• 分子量: 614.828
• InChiKey: RNRQSUGBTSUMFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  45
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  91.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-{[1-phenyl-4-(3-methoxyphenyl)piperidin-4-yl]methyl}-N'-(4-tert-butoxycarbonylamino-2,6-diisopropylphenyl)urea 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 N-{[1-phenyl-4-(3-hydroxyphenyl)piperidin-4-yl]methyl}-N'-(4-amino-2,6-diisopropylphenyl)urea
  参考文献：
  名称：

  EP1500648

  摘要：

  公开号：
• 作为产物：
  描述：

  tert-butyl 4-nitrophenyl (2,6-diisopropyl-1,4-phenylene)biscarbamate 、 [1-phenyl-4-(3-methoxyphenyl)piperidin-4-yl]-methylamine 以 四氢呋喃 为溶剂， 生成 N-{[1-phenyl-4-(3-methoxyphenyl)piperidin-4-yl]methyl}-N'-(4-tert-butoxycarbonylamino-2,6-diisopropylphenyl)urea
  参考文献：
  名称：

  EP1500648

  摘要：

  公开号：

文献信息

• Novel piperidine derivative
  申请人：Ban Hitoshi

  公开号：US20050165057A1

  公开（公告）日：2005-07-28

  A compound of the formula (1): wherein m and n are independently an integer of 0 to 4, and m+n=4; L is cycloalkyl, substituted cycloalkyl, aromatic group, or substituted aromatic group; Y is aryl or substituted aryl; R is hydrogen, alkyl, etc.; R 31 , R 32 , R 33 , R 34 , R 35 and R 36 are the same or different and are selected, if two or more exist, independently from hydrogen, alkyl, etc., or a prodrug thereof, or a pharmaceutically acceptable salt of the same, which exhibits ACAT inhibitory activity, and is useful as an agent for treatment of hyperlipidemia and atherosclerosis.

  化合物的式子(1): 其中m和n独立地是0到4之间的整数，且m+n=4；L是环烷基，取代环烷基，芳香族基或取代芳香族基；Y是芳基或取代芳基；R是氢，烷基等；R31、R32、R33、R34、R35和R36相同或不同，如果存在两个或更多，则独立地从氢，烷基等中选择，或其前药，或其药学上可接受的盐，其表现出ACAT抑制活性，并且用作治疗高脂血症和动脉粥样硬化的药物。
• NOVEL PIPERIDINE DERIVATIVE
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP1500648A1

  公开（公告）日：2005-01-26

  A compound of the formula (1): wherein m and n are independently an integer of 0 to 4, and m+n=4; L is cycloalkyl, substituted cycloalkyl, aromatic group, or substituted aromatic group; Y is aryl or substituted aryl; R is hydrogen, alkyl, etc.; R31, R32, R33, R34, R35 and R36 are the same or different and are selected, if two or more exist, independently from hydrogen, alkyl, etc., or a prodrug thereof, or a pharmaceutically acceptable salt of the same, which exhibits ACAT inhibitory activity, and is useful as an agent for treatment of hyperlipidemia and atherosclerosis.

  式（1）的化合物： 其中 m 和 n 独立地为 0 至 4 的整数，且 m+n=4 ；L 为环烷基、取代环烷基、芳香基团或取代芳香基团；Y 为芳基或取代芳基；R 为氢、烷基等；R31、R32、R33、R34、R35 和 R36 相同或不同，且如果存在两个或多个，则独立地选自氢、烷基等、 或其原药，或其药学上可接受的盐，具有 ACAT 抑制活性，可作为治疗高脂血症和动脉粥样硬化的药物。
• Synthesis and structure–activity relationships of N-(4-amino-2,6-diisopropylphenyl)-N’-(1,4-diarylpiperidine-4-yl)methylureas as anti-hyperlipidemic agents
  作者：Shigehiro Asano、Hitoshi Ban、Koichi Kino、Katsuhisa Ioriya、Masami Muraoka

  DOI：10.1016/j.bmc.2009.04.059

  日期：2009.7

  Based on 1,4-diarylpiperidine-4-methylureas, a new class of ACAT inhibitors, we examined in the study the SAR of a series of compounds prepared by replacing the substituent at the three aromatic parts. Introduction of long alkoxy group onto the phenyl moiety at the B-part was effective in improving both the inhibitory activity for ACAT and the up-regulatory activity for LDL-R expression. Particularly, 3-hydroxy-propoxy group (43) on the phenyl moiety of B-part led to improved solubility, while keeping both biological activities. Compound 43 inhibited ACAT activity with an IC(50) value of 18 nM, which is superior to that of a known ACAT inhibitor, CI-1011. In addition, compound 43 revealed an LDL-R up-regulatory activity comparable to that of SMP-797. We therefore expect this compound to be a novel ACAT inhibitor. (C) 2009 Elsevier Ltd. All rights reserved.
• Novel 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: Dual effectors on acyl-CoA:cholesterol O-acyltransferase and low-density lipoprotein receptor expression
  作者：Shigehiro Asano、Hitoshi Ban、Kouichi Kino、Katsuhisa Ioriya、Masami Muraoka

  DOI：10.1016/j.bmcl.2009.01.020

  日期：2009.2

  A family of 1,4-diarylpiperidine-4-methylureas were designed and synthesized as novel dual effectors on ACAT and LDL receptor expression. We examined SAR of the synthesized compounds focusing on substitution at the three aromatic parts of the starting compound 1 and succeeded in identifying essential substituents for inhibition of ACAT and up-regulation of hepatic LDL receptor expression. Especially, we found that compound 12f, which can easily be prepared, has biological properties comparable to those of SMP-797, a promising ACAT inhibitor. In addition, the in vitro effects of 12f on lipid metabolism were substantially superior to those of a known ACAT inhibitor, Avasimibe. (C) 2009 Elsevier Ltd. All rights reserved.
• EP1500648
  申请人：——

  公开号：——

  公开（公告）日：——